Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 5 | 2024 | 231 | 1.600 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 54 | 0.970 |
Why?
|
| Bayes Theorem | 8 | 2024 | 79 | 0.960 |
Why?
|
| Ohio | 6 | 2021 | 58 | 0.790 |
Why?
|
| Decision Making | 1 | 2023 | 194 | 0.750 |
Why?
|
| Patient Admission | 2 | 2019 | 60 | 0.690 |
Why?
|
| Research Design | 2 | 2023 | 310 | 0.650 |
Why?
|
| Population Surveillance | 1 | 2019 | 125 | 0.630 |
Why?
|
| Humans | 38 | 2024 | 31836 | 0.550 |
Why?
|
| Data Collection | 1 | 2015 | 180 | 0.510 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 409 | 0.490 |
Why?
|
| Adolescent | 11 | 2021 | 3511 | 0.480 |
Why?
|
| Adult | 17 | 2022 | 9327 | 0.430 |
Why?
|
| Male | 28 | 2023 | 19091 | 0.410 |
Why?
|
| Female | 28 | 2023 | 19859 | 0.400 |
Why?
|
| Middle Aged | 17 | 2022 | 11824 | 0.400 |
Why?
|
| Coronary Disease | 3 | 2022 | 213 | 0.380 |
Why?
|
| Hydrocortisone | 2 | 2021 | 57 | 0.360 |
Why?
|
| Young Adult | 8 | 2019 | 2603 | 0.340 |
Why?
|
| Length of Stay | 3 | 2019 | 315 | 0.340 |
Why?
|
| Upper Extremity | 2 | 2019 | 57 | 0.320 |
Why?
|
| Blood Glucose | 3 | 2020 | 491 | 0.320 |
Why?
|
| Bacterial Infections | 2 | 2018 | 52 | 0.300 |
Why?
|
| Stroke | 3 | 2022 | 581 | 0.280 |
Why?
|
| United States | 4 | 2024 | 3925 | 0.280 |
Why?
|
| Aged | 14 | 2021 | 10288 | 0.280 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 471 | 0.270 |
Why?
|
| Heroin | 1 | 2024 | 21 | 0.240 |
Why?
|
| African Americans | 3 | 2021 | 1428 | 0.240 |
Why?
|
| Prevalence | 3 | 2023 | 979 | 0.230 |
Why?
|
| Hepatitis C | 1 | 2023 | 41 | 0.220 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 43 | 0.220 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 127 | 0.210 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 47 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 10 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3488 | 0.190 |
Why?
|
| Prognosis | 3 | 2019 | 1498 | 0.180 |
Why?
|
| Child | 7 | 2020 | 2425 | 0.180 |
Why?
|
| Advance Care Planning | 1 | 2020 | 15 | 0.180 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.180 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.180 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 7 | 0.180 |
Why?
|
| Acute Disease | 2 | 2018 | 252 | 0.170 |
Why?
|
| Allostasis | 1 | 2019 | 12 | 0.170 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.170 |
Why?
|
| Adiposity | 1 | 2021 | 198 | 0.170 |
Why?
|
| Aldosterone | 1 | 2019 | 26 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2022 | 461 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 32 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2019 | 12 | 0.170 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 14 | 0.170 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 7 | 0.170 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 49 | 0.170 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.170 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2019 | 12 | 0.160 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 5 | 0.160 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 43 | 0.160 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 8 | 0.160 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 3 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 39 | 0.160 |
Why?
|
| Muscular Diseases | 1 | 2018 | 22 | 0.160 |
Why?
|
| Paresis | 1 | 2018 | 13 | 0.160 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 4 | 0.160 |
Why?
|
| Child Abuse | 1 | 2019 | 27 | 0.160 |
Why?
|
| Foot | 1 | 2018 | 39 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 186 | 0.160 |
Why?
|
| Cohort Studies | 5 | 2022 | 1824 | 0.160 |
Why?
|
| HIV Infections | 1 | 2023 | 394 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 25 | 0.160 |
Why?
|
| Motor Neurons | 1 | 2018 | 56 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 73 | 0.160 |
Why?
|
| Fever | 1 | 2018 | 61 | 0.160 |
Why?
|
| Parkinson Disease | 1 | 2019 | 82 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 63 | 0.160 |
Why?
|
| Age Factors | 5 | 2019 | 1187 | 0.160 |
Why?
|
| Child, Preschool | 5 | 2019 | 1259 | 0.160 |
Why?
|
| Muscle Contraction | 1 | 2018 | 113 | 0.160 |
Why?
|
| Pediatrics | 1 | 2020 | 157 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 771 | 0.150 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.150 |
Why?
|
| Exercise Test | 1 | 2019 | 225 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2017 | 19 | 0.150 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 14 | 0.150 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 22 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2019 | 191 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 44 | 0.150 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 178 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2019 | 2277 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2022 | 767 | 0.130 |
Why?
|
| Depression | 1 | 2019 | 442 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 351 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 109 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 200 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 2146 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 513 | 0.120 |
Why?
|
| Ribonucleases | 1 | 2012 | 4 | 0.110 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 6 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 924 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 44 | 0.100 |
Why?
|
| Organogenesis | 1 | 2012 | 15 | 0.100 |
Why?
|
| Skin Tests | 1 | 2011 | 12 | 0.100 |
Why?
|
| Infant | 3 | 2019 | 1055 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2011 | 25 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 3851 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1122 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 899 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 2012 | 182 | 0.090 |
Why?
|
| Electromyography | 2 | 2018 | 59 | 0.080 |
Why?
|
| Hand Strength | 2 | 2018 | 100 | 0.080 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 40 | 0.080 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 45 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 662 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 686 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1527 | 0.070 |
Why?
|
| Accidental Falls | 2 | 2019 | 221 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 537 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 63 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1192 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3988 | 0.060 |
Why?
|
| Appalachian Region | 1 | 2023 | 17 | 0.060 |
Why?
|
| Massachusetts | 1 | 2023 | 27 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2023 | 107 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 83 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2271 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 41 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 291 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 764 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 68 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 173 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 183 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 90 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 63 | 0.050 |
Why?
|
| Saliva | 1 | 2020 | 36 | 0.050 |
Why?
|
| Adiponectin | 1 | 2021 | 106 | 0.050 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 47 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 95 | 0.040 |
Why?
|
| Algorithms | 1 | 2023 | 495 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Documentation | 1 | 2020 | 46 | 0.040 |
Why?
|
| Mice | 2 | 2018 | 2476 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3294 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 27 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 27 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 21 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 3 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 98 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 20 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 15 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 12 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 44 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 105 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 37 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 5 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 238 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 79 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 293 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 400 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 71 | 0.040 |
Why?
|
| Animals | 3 | 2018 | 7450 | 0.040 |
Why?
|
| Poverty | 1 | 2019 | 111 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 119 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 72 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 284 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 261 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 183 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 238 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 177 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 124 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2017 | 32 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 756 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 874 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 47 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 518 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2016 | 17 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2019 | 665 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 127 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 593 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 300 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 287 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 190 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 766 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 390 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 181 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 238 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 566 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 349 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1012 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1158 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 629 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1169 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 480 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 14 | 0.030 |
Why?
|
| Heart Failure | 1 | 2019 | 620 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 99 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 247 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 52 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 70 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 55 | 0.020 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2011 | 3 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 2 | 0.020 |
Why?
|
| Poaceae | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 208 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 334 | 0.020 |
Why?
|
| Allergens | 1 | 2011 | 17 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 132 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1431 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 398 | 0.020 |
Why?
|